** Biotech firm Celcuity's CELC.O shares up 1.2% at $90 on Thurs after securing capital raise

** Minneapolis, Minnesota-based firm late Weds announced pricing public offering of $500 mln 0.25% convertible bonds due 2032

** Offering size increased from $400 mln; initial conversion price of $124.53 set 40% above stock's last close

** Co intends to use net offering proceeds from the CBs to fully repay loan with Oxford Finance, LLC, and remainder for working capital and general purposes

** Jefferies, JP Morgan, TD Cowen and Guggenheim joint bookrunners

** Raise comes after CELC shares plunged ~26% to close at $91.42 on Tues after its experimental breast cancer treatment underperformed a previous trial

** Gedatolisib, in combination with Pfizer's PFE.N Ibrance and AstraZeneca's AZN.L endocrine therapy Faslodex was tested in advanced breast cancer patients; the triple-drug combo extended progression-free survival (PFS) by 11.1 months compared to 5.6 months in patients who received Faslodex and Novartis' NOVN.S Piqray

** CELC shares now down ~10% YTD. Stock was trading around $12 a year ago

** Of 12 analysts, 5 rate the stock "strong buy", 7 rate "buy"; median PT $160, per LSEG data